law16175

Chapter 175

2016 -- S 2460 SUBSTITUTE A AS AMENDED
Enacted 06/28/2016

A N A C T

RELATING TO INSURANCE -- ACCIDENT AND SICKNESS INSURANCE POLICIES

Introduced By: Senators Miller, Coyne, Satchell, Jabour, and Nesselbush

Date Introduced: February 11, 2016

It is enacted by the General Assembly as follows:

SECTION 1. Chapter 27-18 of the General Laws entitled "Accident and Sickness

Insurance Policies" is hereby amended by adding thereto the following section:

27-18-82. Opioid antagonists. -- (a) Every individual or group health-insurance contract,

plan, or policy that provides prescription coverage that is delivered, issued for delivery, amended

or renewed in this state on or after January 1, 2017, shall provide coverage for at least one generic

opioid antagonist and device. Prior authorization may be required for non-generic forms of opioid

antagonists and devices.

(b) As used in this section:

"Opioid antagonist" means naloxone hydrochloride and any other drug approved by the

United States Food and Drug Administration for the treatment of opioid overdose.

prescribed or dispensed via standing order or collaborative-practice agreement intended for use

on patients other than the insured. Prior authorization may be required for non-generic forms of

opioid antagonists and devices.

(d) Notwithstanding §27-18-19, or any other provision to the contrary, this section shall

apply to blanket or group polices of insurance.

SECTION 2. Chapter 27-19 of the General Laws entitled "Nonprofit Hospital Service

Corporations" is hereby amended by adding thereto the following section:

27-19-73. Opioid antagonists. -- (a) Every individual or group health-insurance contract,

plan, or policy that provides prescription coverage that is delivered, issued for delivery, amended,

or renewed in this state on or after January 1, 2017, shall provide coverage for at least one generic

opioid antagonist and device. Prior authorization may be required for non-generic forms of opioid

antagonists and devices.

(b) As used in this section:

"Opioid antagonist" means naloxone hydrochloride and any other drug approved by the

United States Food and Drug Administration for the treatment of opioid overdose.

prescribed or dispensed via standing order or collaborative-practice agreement intended for use

on patients other than the insured. Prior authorization may be required for non-generic forms of

opioid antagonists and devices.

SECTION 3. Chapter 27-20 of the General Laws entitled "Nonprofit Medical Service

Corporations" is hereby amended by adding thereto the following section:

27-20-69. Opioid antagonists. -- (a) Every individual or group health-insurance contract,

plan, or policy that provides prescription coverage that is delivered, issued for delivery, amended,

or renewed in this state on or after January 1, 2017, shall provide coverage for at least one generic

opioid antagonist and device. Prior authorization may be required for non-generic forms of opioid

antagonists and devices.

(b) As used in this section:

"Opioid antagonist" means naloxone hydrochloride and any other drug approved by the

United States Food and Drug Administration for the treatment of opioid overdose.

prescribed or dispensed via standing order or collaborative practice agreement intended for use on

patients other than the insured. Prior authorization may be required for non-generic forms of

opioid antagonists and devices.

SECTION 4. Chapter 27-41 of the General Laws entitled "Health Maintenance

Organizations" is hereby amended by adding thereto the following section:

27-41-86. Opioid antagonists. -- (a) Every individual or group health-insurance contract,

plan, or policy that provides prescription coverage that is delivered, issued for delivery, amended,

or renewed in this state on or after January 1, 2017, shall provide coverage for at least one generic

opioid antagonist and device. Prior authorization may be required for non-generic forms of opioid

antagonists and devices.

(b) As used in this section:

"Opioid antagonist" means naloxone hydrochloride and any other drug approved by the

United States Food and Drug Administration for the treatment of opioid overdose.

prescribed or dispensed via standing order or collaborative-practice agreement intended for use

on patients other than the insured. Prior authorization may be required for non-generic forms of

opioid antagonists and devices.

SECTION 5. This act shall take effect on January 1, 2017.

========

LC004770/SUB A

========